Five Things Industry Can Do to Support True FDA Reform, and Restore Public Confidence |

Five Things Industry Can Do to Support True FDA Reform, and Restore Public Confidence

   

 

Five Things Industry Can Do to Support True FDA Reform, and Restore Public Confidence (written by Luke Timmerman @ Xconomy)

1. Support an increase in the FDA budget.

2. Voluntarily ban all direct-to-consumer TV advertising.

3. Support legislation to ban FDA advisory committee members with conflicts of interest.

4. Full disclosure of FDA complete response letters.

5. Finance strong “regulatory science” programs at U.S. business schools and medical schools.

 

The FDA is one of the easiest punching bags in American politics. Depending on your point of view, it’s either too hard on business with its unreasonable demands, or too soft on those predatory drug companies seeking to profit off Grandma’s illness regardless of whether the products are safe.

When it does its job well, the FDA is like an umpire in baseball. Nobody notices. When it screws up, it’s screaming headline news. The polls show various scandals have taken a toll: About half of the U.S. public thinks the FDA is doing a bad job, and the perceptions are that drug companies put profits ahead of patients.

Not surprisingly, the FDA spends most of its time in a defensive crouch, fending off attacks from all angles, generally resisting most change. But last week it did an unusual thing, by sticking its neck out a couple inches. It suggested, in a 40-page strategic outline, a few ideas for how it can do a better job stimulating (not smothering) life sciences innovation in the U.S. It intends to do this while also ensuring the safety and effectiveness of new medical products.

FDA commissioner Margaret Hamburg has been feeling pressure behind the scenes from venture capitalists and their industry allies for the past 18 months or so. Sure enough, a day after she released the FDA report, the National Venture Capital Association released results of a surveythat said the FDA—plagued by long delays, unpredictable decisions, poor communication, and excessive caution in new product reviews—has become the No. 1 reason why 40 percent of U.S. venture capitalists have cut their investments in life sciences the past three years, and that the same percentage plan to continue cutting U.S. investment the next three years. Jobs have been lost, and even more will be shipped overseas unless something is done at the FDA, the investors said.

Developing new drugs or medical devices has always taken a long time, cost a lot of money, and been risky. But it’s gotten worse lately. Government and industry now pour $95 billion a year into biomedical R&D, and somehow society keeps getting a stagnant number of new drugs coming out the other end. It’s a serious concern for patients.

The FDA’s report has some sensible, albeit small-bore, non-controversial ideas about how it can do a better job making this whole process work better. It says it wants to improve its outreach to small businesses; create a fast approval pathway for certain targeted therapies; improve data sharing among its divisions; and better train its scientific reviewers. The report is light on the details, but at least one VC who’s been active in pushing for FDA reform said it’s a start.

FDA commissioner Margaret Hamburg

“The FDA has finally acknowledged it has been a damper on innovation and has hurt the ability of American companies to grow and be competitive,” says Ross Jaffe, a managing director with Versant Ventures, a life sciences venture firm with $1.6 billion under management. “It’s an encouraging sign that things may hopefully things will start getting better,” he says, adding that the FDA of today doesn’t respect its own prior precedents, adds unpredictable new requirements, and seems oblivious to the time and money it takes businesses to respond to its questions.

I worry that the FDA could get distracted from its main job of ensuring product safety and effectiveness, if it cares too much about industry’s wishes. And there are plenty of companies willing to cut corners and do the quick-and-dirty thing whenever they can slip it by the FDA, so there has to be a well-resourced, tough watchdog on alert.

But if VCs and biotech and pharma lobbies are really serious about reforming the FDA, so that it can be a tough-but-fair regulator that instills public confidence in healthcare products, then the industry needs to quit heaping all the blame on the FDA and start accepting some responsibility of its own. The FDA depends on taxpayer support, so it needs to be sensitive to public sentiment. If the public is more confident in a more accountable FDA, I think you’d get a more efficient and predictable body.

Here are five suggestions for accomplishing that (many of which have been bandied about widely before) that I think the industry could get behind:

1. Support an increase in the FDA budget. Industry at various points in time has supported this idea, and has agreed to pay a lot in application user fees, but always with strings, and never much enthusiasm. Just for perspective, the agency requested a $4 billion budget for fiscal 2011, less than half of what the nation spends each year on the Coast Guard. Trying to regulate one-fourth of the economy takes a lot of money. Even after numerous safety debacles (Vioxx, Avandia), the FDA still doesn’t have a serious modern database that can capture and analyze data on adverse drug reactions for marketed pharmaceuticals in the U.S. It’s truly a national embarrassment that so little effort has gone into solving this problem. Adverse event reports are starting to spill out into the open from patients on Facebook, and nobody really knows what do about it. I just wrote recently about a California startup that is building a deep adverse events database on its own, with a plan to charge for access. The FDA ought to be able to do this itself, and bring its outdated Medwatch system into the 21st century. It ought to catch safety problems in something close to real-time, and update drug warning labels accordingly. And the industry should support this because it’s the right thing to do.

2. Voluntarily ban all direct-to-consumer TV advertising. Pharma companies helped create a new public perception about pharmaceuticals in the last decade through their annoying and misleading TV ads. The pharma companies helped create the national expectation, through ads that exaggerate benefits and downplay risks, that prescription drugs are like taking Honey Nut Cheerios. So guess what? People get righteously indignant and shocked when they find out that the drug that’s supposed to help you dance at your daughter’s wedding actually raises your risk of heart attack and stroke. These ads have created a monstrous public perception, undermined the doctor/patient relationship, and been a huge boon to personal injury lawyers. If drug companies voluntarily pulled all the ads, and were a little more forthright about the risks and benefits of medical products, I bet the public would be a lot more understanding when things go wrong, and that the FDA would take a more balanced approach to reviewing safety of new products.

3. Support legislation to ban FDA advisory committee members with conflicts of interest. The pharma industry has done a lot of unseemly things over the years, and one of them has been systematically putting money in the pockets of leading U.S. physicians in an attempt to curry favor with these “thought leaders,” so they will influence peers to prescribe certain new drugs. Many of these same thought leaders then sit in judgment of products on FDA advisory panels. The FDA has said that it needs to get advice from these experts who are on the take because it’s the only way to get expert advice. That’s bull. Pharma, and the FDA should join together in an effort to reform the advisory committee process and find independent experts. Again, that could help restore public confidence in the FDA, and by extension, the industry.

4. Full disclosure of FDA complete response letters. Right now, when the FDA turns down an application for a drug or device, its sends a letter to companies that isn’t a public record. The FDA doesn’t bother to explain most of these decisions, leaving that up to the companies to communicate. And what happens is the companies try to spin the contents of the letter, often telling the public that it’s all the fault of that unpredictable FDA. Maybe it is, maybe it isn’t. Maybe the FDA has a point that it isn’t getting as many good applications anymore. Maybe the companies themselves are just covering up some embarrassing failures of their own. Open up these complete response letters, and let the public see why the FDA made those decisions. The FDA itself has suggested this, but you don’t hear industry arguing publicly in favor of full transparency. Again, it would be a big confidence builder in the whole drug development review process.

5. Finance strong “regulatory science” programs at U.S. business schools and medical schools. It’s one thing to complain about how the FDA doesn’t have business savvy, and it’s another to do something about it. How about supporting programs at medical and business schools in emerging disciplines like regulatory science? One leading biotech industry veteran, UCSF Chancellor Susan Desmond-Hellmann, has advocated for this discipline, which seeks to help basic science ideas navigate the tough process to become products. How about putting your money where your mouth is, by supporting such programs that can help train young people who can then put those skills to work at the FDA, and inside your own companies? I’ve been hearing for years about a shortage of qualified people to work in regulatory affairs. Given the unemployment situation in the U.S., it makes a lot of sense to start training more people in this important discipline.

Leave a Reply

Your email address will not be published. Required fields are marked *